1. Home
  2. PCT vs XERS Comparison

PCT vs XERS Comparison

Compare PCT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PureCycle Technologies Inc.

PCT

PureCycle Technologies Inc.

HOLD

Current Price

$7.15

Market Cap

1.4B

Sector

Utilities

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.42

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCT
XERS
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PCT
XERS
Price
$7.15
$8.42
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$13.00
$10.83
AVG Volume (30 Days)
4.3M
1.6M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
30.86
100.00
EPS
N/A
N/A
Revenue
$8,355,000.00
$49,590,000.00
Revenue This Year
$380.44
$34.37
Revenue Next Year
$203.33
$22.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
142.67
52 Week Low
$4.93
$5.25
52 Week High
$15.49
$10.08

Technical Indicators

Market Signals
Indicator
PCT
XERS
Relative Strength Index (RSI) 50.03 55.68
Support Level $5.02 $6.98
Resistance Level $9.56 $8.42
Average True Range (ATR) 0.48 0.32
MACD 0.18 -0.02
Stochastic Oscillator 61.19 82.73

Price Performance

Historical Comparison
PCT
XERS

About PCT PureCycle Technologies Inc.

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: